Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
BRIEF-Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2 Oct 20 (Reuters) - Alcon AG ALCC.S:
ALCON ACQUIRES NEUROTECH AND ENCELTO, THE ONLY FDA-APPROVED TREATMENT FOR MACTEL TYPE 2
ALCON AG - PAYS $550 MILLION TO BUY NEUROTECH PHARMACEUTICALS
ALCON AG - MAY MAKE ADDITIONAL CONTINGENT PAYMENTS FOR COMMERCIAL MILESTONES
ALCON AG: EXPECTS TRANSACTION TO BE MODESTLY ACCRETIVE TO NET SALES GROWTH AND SLIGHTLY DILUTIVE TO CORE DILUTED EPS IN 2027
ALCON AG: EXPECTS TRANSACTION TO BE ACCRETIVE AFTER 2027
Source text: ID:nBw9JjnLba
Further company coverage: ALCC.S
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Alcon AG
See all newsSwiss stocks - Factors to watch on November 12
Alcon AG reports results for the quarter ended September 30 - Earnings Summary
Alcon shares fall as tighter eye-care market outlook raises growth concerns (updated)
Alcon seen down after sales miss, tighter outlook
Swiss stocks - Factors to watch on November 11